Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Oct;26(4):423–428. doi: 10.1111/j.1365-2125.1988.tb03401.x

Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

R O Day 1, J O Miners 1, D J Birkett 1, A Whitehead 1, D Naidoo 1, J Hayes 1, E Savdie 1
PMCID: PMC1386564  PMID: 3190992

Abstract

1. Allopurinol usage in 50 patients of a city teaching hospital was surveyed. 2. The plasma concentrations of oxipurinol and uric acid and the urinary production of uric acid were examined. 3. The daily doses of allopurinol ranged from 50 to 1200 mg but 83% of patients were taking 300 mg daily. 4. A wide range of plasma oxipurinol concentrations was observed from 2.8 to 55.8 mg l-1 with a mean +/- s.d. of 15.2 +/- 11.7 mg l-1. 5. The population studied included a high proportion of patients with renal impairment and creatinine clearance was a significant determinant of oxipurinol concentrations (P less than 0.005). 6. There was no significant correlation between plasma urate and plasma oxipurinol concentrations and only a few plasma urates were above the upper limit of the reference range of the laboratory. 7. It was apparent that many patients were taking unnecessarily high daily doses of allopurinol and that renal status was not always considered when deciding dosage regimens of allopurinol.

Full text

PDF
423

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkett D. J., Miners J. O., Attwood J. Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid. Br J Clin Pharmacol. 1983 Jan;15(1):117–119. doi: 10.1111/j.1365-2125.1983.tb01475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cameron J. S., Simmonds H. A. Use and abuse of allopurinol. Br Med J (Clin Res Ed) 1987 Jun 13;294(6586):1504–1505. doi: 10.1136/bmj.294.6586.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  4. Elion G. B., Yü T. F., Gutman A. B., Hitchings G. H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968 Jul;45(1):69–77. doi: 10.1016/0002-9343(68)90008-9. [DOI] [PubMed] [Google Scholar]
  5. Emmerson B. T., Gordon R. B., Cross M., Thomson D. B. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987 Dec;26(6):445–449. doi: 10.1093/rheumatology/26.6.445. [DOI] [PubMed] [Google Scholar]
  6. Hande K. R., Noone R. M., Stone W. J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47–56. doi: 10.1016/0002-9343(84)90743-5. [DOI] [PubMed] [Google Scholar]
  7. Hande K., Reed E., Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978 May;23(5):598–605. doi: 10.1002/cpt1978235598. [DOI] [PubMed] [Google Scholar]
  8. Kramer W. G., Feldman S. High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma. J Chromatogr. 1979 Jan 1;162(1):94–97. doi: 10.1016/s0378-4347(00)82068-x. [DOI] [PubMed] [Google Scholar]
  10. Scott J. T. Asymptomatic hyperuricaemia. Br Med J (Clin Res Ed) 1987 Apr 18;294(6578):987–988. doi: 10.1136/bmj.294.6578.987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Singer J. Z., Wallace S. L. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986 Jan;29(1):82–87. doi: 10.1002/art.1780290111. [DOI] [PubMed] [Google Scholar]
  12. Spector T. Inhibition of urate production by allopurinol. Biochem Pharmacol. 1977 Mar 1;26(5):355–358. doi: 10.1016/0006-2952(77)90191-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES